- Home
- ARCT vs EYPT Comparison
ARCT vs EYPT Comparison
Compare ARCT & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCT
- EYPT
- Stock Information
- Founded
- ARCT 2013
- EYPT 1987
- Country
- ARCT United States
- EYPT United States
- Employees
- ARCT N/A
- EYPT N/A
- Industry
- ARCT Biotechnology: Pharmaceutical Preparations
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- ARCT Health Care
- EYPT Industrials
- Exchange
- ARCT Nasdaq
- EYPT Nasdaq
- Market Cap
- ARCT 298.3M
- EYPT 579.4M
- IPO Year
- ARCT N/A
- EYPT 2005
- Fundamental
- Price
- ARCT $13.78
- EYPT $10.36
- Analyst Decision
- ARCT Strong Buy
- EYPT Strong Buy
- Analyst Count
- ARCT 8
- EYPT 8
- Target Price
- ARCT $52.83
- EYPT $24.75
- AVG Volume (30 Days)
- ARCT 474.9K
- EYPT 811.1K
- Earning Date
- ARCT 08-04-2025
- EYPT 08-06-2025
- Dividend Yield
- ARCT N/A
- EYPT N/A
- EPS Growth
- ARCT N/A
- EYPT N/A
- EPS
- ARCT N/A
- EYPT N/A
- Revenue
- ARCT $143,680,000.00
- EYPT $56,042,000.00
- Revenue This Year
- ARCT N/A
- EYPT N/A
- Revenue Next Year
- ARCT $34.79
- EYPT N/A
- P/E Ratio
- ARCT N/A
- EYPT N/A
- Revenue Growth
- ARCT 15.38
- EYPT 12.04
- 52 Week Low
- ARCT $8.04
- EYPT $3.91
- 52 Week High
- ARCT $25.88
- EYPT $13.99
- Technical
- Relative Strength Index (RSI)
- ARCT 54.34
- EYPT 61.63
- Support Level
- ARCT $13.10
- EYPT $9.45
- Resistance Level
- ARCT $15.20
- EYPT $11.69
- Average True Range (ATR)
- ARCT 1.02
- EYPT 0.83
- MACD
- ARCT 0.07
- EYPT 0.03
- Stochastic Oscillator
- ARCT 55.21
- EYPT 64.53
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.